Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home Medicines & Healthy Lifestyle

Deoxycytidine Kinase Inhibitor Designated Orphan Drug for Optic Neuritis

admin by admin
August 13, 2022
in Medicines & Healthy Lifestyle


The Food and Drug Administration (FDA) has granted Orphan Drug designation to TRE-515 for the treatment of demyelinating optic neuritis.

Optic neuritis (ON) is a rare autoimmune disease characterized by the inflammation of the optic nerve. The condition can lead to rapid loss of vision in one or both eyes. TRE-515 is a potential first-in-class, orally administered, small molecule inhibitor of deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway. 

“Inflammation damaging the protective myelin coating around the optic nerve causes ON, leading to pain and vision loss,” said Dr Peter Clark, member of the Trethera Scientific Advisory Board. “Targeting dCK with TRE-515 could limit this inflammation.”


Continue Reading

The FDA’s Orphan Drug designation is granted to medicines intended to treat or prevent rare diseases or disorders that affect fewer than 200,000 individuals.

“TRE-515 could potentially significantly benefit ON patients beyond the available therapeutic options, especially those taking long-term steroids,” said Trethera Scientific Advisory Board member Dr Larry Steinman.

Reference

Trethera announces FDA Orphan Drug designation granted to TRE-515 for the treatment of demyelinating optic neuritis. News release. Trethera Corporation. Accessed August 11, 2022. https://www.globenewswire.com/news-release/2022/08/09/2495188/0/en/Trethera-Announces-FDA-Orphan-Drug-Designation-Granted-to-TRE-515-for-the-Treatment-of-Demyelinating-Optic-Neuritis.html

This article originally appeared on MPR

Topics:

Immune Disorders
Ophthalmic Disorders



Source link

Previous Post

CDC Introduces Streamlined Guidelines For Better COVID-19 Protection, Understanding

Next Post

Health Bulletin 12/August/2022

Next Post

Health Bulletin 12/August/2022

Recommended

Dapagliflozin Beneficial Regardless of Ejection Fraction in HF

August 30, 2022

How Sugar Harms Your Brain and Drives Alzheimer’s Epidemic

January 7, 2023

Don't miss it

Pharmaceutical

Strange bedfellows lobby for Medicare obesity-drug coverage

January 26, 2023
Medicines & Healthy Lifestyle

FDA Panel Votes on Rezafungin for Treatment of Candidemia, Invasive Candidiasis

January 26, 2023
Medicines & Healthy Lifestyle

This Cancer Drug Can Increase Longevity, Study Finds

January 26, 2023
News

Something in Breast Milk Helps Protect Babies Against Allergies

January 26, 2023
Pharmaceutical

Merck ends late-stage trial for Keytruda in prostate cancer

January 25, 2023
Medicines & Healthy Lifestyle

Are Seed Oils Behind the Majority of Diseases This Century?

January 25, 2023

© 2022 Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.